Recent data have confirmed the negative impact of preformed donor-specific antibodies (pDSAs) after liver transplantation (LT). In order to reduce the risk of developing lesions associated with acute and chronic antibody-mediated rejection in LT recipients, we evaluated the consequences in terms of transplant accessibility, associated with avoiding pDSAs according to several mean fluorescence intensity (MFI) titer thresholds that have been previously reported to be relevant in LT. Among the 484 included LT candidates, 99 (20.5%) presented with anti-human leukocyte antibodies (HLAs). The predictive factors for anti-HLA sensitization were a history of previous kidney transplantation (odds ratio [OR], 1.5; 95% confidence interval [CI], 1.30-1.9; P 5 0.05), a history of previous LT (OR, 1.9; 95% CI, 1.6-2.1; P 5 0.01), a history of blood transfusion (OR, 2.5; 95% CI, 2.2-4.1; P 5 0.01), and a history of pregnancy (OR, 2.9; 95% CI, 2.4-3.3; P 5 0.04). By applying a strategy of unacceptable mismatches for recipients with an antibody (Ab) MFI of > 5000, only 35 patients were affected (7% of the cohort), but 22 of these (63%) would have been considered incompatible with >50% of the donors. Using a MFI threshold of >10,000, only 16 patients were affected (1.4% of the cohort), but half of these would have been considered incompatible with >50% of the proposed donors. Considering only those with anti-class II Ab and a MFI >5000 and >10,000, respectively, 10/14 and 4/8 patients were considered incompatible with >50% of the donors. In conclusion, avoiding pDSAs affects a small but not negligible proportion of LT candidates. However, in these sensitive patients, avoiding pDSAs has the potential to significantly reduce the donor pool and, consequently, transplant accessibility.
Recent data have confirmed the negative impact of preformed donor-specific antibodies (pDSAs) after liver transplantation (LT). (1, 2) Most pDSAs with a mean fluorescence intensity (MFI) of < 10,000 become undetectable shortly after transplantation. (3) However, pDSAs in almost half of patients who have anti-class II pDSAs with a MFI score >10,000 remain detectable after transplantation. (3) Among these, some recipients (<5% of patients with pDSAs) will develop acute graft dysfunction related to antibody-mediated rejection (aAMR). (2, 4) A positive crossmatch, multiple pDSAs, and a high MFI score are predictive factors for aAMR. (2, 3, 5) Moreover, it has been suggested that Immunoglobulin G3 (IgG3) subclasses of DSAs and complement 1q (C1q)-fixing DSAs are associated with increased risks of allograft damage. (6, 7) aAMR is a severe complication after LT. Despite appropriate treatment with a B cell targeting agent, associated with increased immunosuppressive treatment, mitigated results are reported, with a high risk of graft failure that requires retransplantation in some Abbreviations: aAMR, antibody-mediated rejection; Ab, antibody; AIH, autoimmune hepatitis; cAMR, chronic liver antibody-mediated rejection; CI, confidence interval; C1q, complement 1q; DSA, donorspecific anti-HLA antibodies; HBV, hepatitis B virus; HCV, hepatitis C virus; HLA, human leukocyte antibody; IgG, immunoglobulin G; Ig3, immunoglobulin G3; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; MFI, mean fluorescence intensity; OR, odds ratio; PBC, primary biliary cirrhosis; pDSA, preformed donor-specific antibody; PSC, primary sclerosing cholangitis.
cases or causes serious complications related to the additional treatments. (1, 8, 9) Moreover, it has been previously reported that chronic liver antibody-mediated rejection (cAMR) can decrease patient and graft survival rates, particularly in recipients with positive anti-class II DSAs. (3, 7, 10) In order to reduce the risk of developing lesions associated with acute and chronic aAMR in LT recipients, we examined the prevalence of sensitization in our patients waiting for a LT. We also evaluated the consequences in terms of transplant accessibility, associated with avoiding pDSAs according to several MFI titer thresholds that have been previously reported to be relevant in LT.
Patients and Methods

PATIENTS
Between February 2008 and January 2016, all 484 candidates awaiting LT in our institution were screened for anti-human leukocyte antibodies (HLAs) every 6 months until transplantation, and at the last follow-up or when exiting the waiting list. Each patient was tested at least once using the Luminex Single-Antigen assay (Luminex, Austin, TX) (median, 1; range, [1] [2] [3] [4] [5] [6] . If a patient was tested several times while on the waiting list, the most recently analyzed serum or that analyzed closest to LT was used. During this period, 326 of the 484 patients received a transplant, 103 patients remained on the waiting list, 39 died while on the waiting list, and 16 patients were excluded because of progression of hepatocellular carcinoma (n 5 10) or a relapse in alcohol consumption (n 5 6). This retrospective study from prospective collected data was approved by the Toulouse Institutional Review Board.
IMMUNOLOGICAL ANALYSES
Luminex assays determined the specificity of class I HLA in A/B and class II in DR/DQ immunoglobulin G (IgG) antibodies (Abs) in the candidate's LT sera (centrifuged at 10,000g for 10 minutes) using LAB-SCREEN single Ag HLA class I and class II detection tests (One Lambda, Canoga Park, CA), according to the manufacturer's instructions. The presence and specificity of Abs were then detected using a LABscan 100, and the mean fluorescence (baseline) value for each sample in each bead was evaluated. The baseline value was calculated as follows: (raw sample MFI -raw negative-serum control MFI) -(negative bead raw MFI sample -negative bead raw MFI-negative serum control). A baseline value of >1000 was considered positive, as previously suggested. (7, 10, 11) 
UNACCEPTABLE MISMATCHES
To evaluate the transplant accessibility of sensitized LT candidates, we calculated the proportion of incompatible grafts that had unacceptable mismatches (among French proposed deceased liver donors in the same blood group), over the previous 5 years for each patient. According to previously published data concerning the risk of aAMR and cAMR, (3, 7, 8) we used MFI values of >5000 and >10,000. Because the risk of having persistent anticlass II anti-HLA pDSAs was high and the risk for AMR was increased in this setting, we only tested the transplant's accessibility if the anti-class II Abs (with MFI scores of >5000 and >10,000) were considered as unacceptable mismatches.
STATISTICAL ANALYSES
Reported values are represented by their means ( 6 standard deviation) or medians (ranges). Proportions were compared using v (2) test or Fisher's exact test when appropriate. Quantitative variables were compared using the Mann-Whitney U nonparametric test or Student t test. The predictive factors for developing anti-HLA were determined using a stepwise multivariate logistic regression. Factors associated, by univariate analyses (at a significance of P < 0.05), with the detection of Abs, were selected for inclusion in the multivariate analyses.
Results
ANTI-HLA SENSITIZATION IN LT CANDIDATES
Among the 484 included LT candidates, 99 (20.5%) presented with at least 1 anti-HLA Ab with a MFI of >1000 (58%, 28%, and 13% directed against class I, II, and I and II antigens, respectively). The patients' characteristics are presented in Table 1 . Forty percent of sensitized patients presented with at least 1 Ab and had a MFI of >5000, and 19% had an Ab with a MFI of >10,000. In the univariate analysis, a history of previous kidney transplantation, LT, pregnancy, or blood transfusion; being female; and an autoimmune cause for liver failure were all associated with anti-HLA sensitization. In the multivariate analysis, the predictive factors for anti-HLA sensitization were a history of previous kidney transplantation (odds ratio [OR], 1.5; 95% confidence interval [CI], 1.30-1.9; P 5 0.05), a history of previous LT (OR, 1.9; 95% CI, 1.6-2.1; P 5 0.01), a history of blood transfusion (OR, 2.5; 95% CI, 2.2-4.1; P 5 0.01), and a history of pregnancy (OR, 2.9; 95% CI, 2.4-3.3; P 5 0.04).
Fifty-six patients were tested at least twice (median, 3; range, 2-6). Among these patients, 8 were sensitized during the follow-up period (median time, 17 months; range, 15-39 months). We did not observe any change concerning anti-HLA screening for Abs with a MFI of >5000, whereas anti-HLA with a MFI of <5000 became undetectable at the last follow-up for 4 patients. The remaining 48 patients without Abs remained unsensitized at the last follow-up (median time, 16 months; range, 13-35 months). 
TRANSPLANTATION WITH pDSAS
INCOMPATIBLE GRAFTS
To assess the impact of not receiving a transplant because of apDSA, we evaluated the occurrence of incompatible grafts over the previous 5 years among proposed deceased liver donors in France who had the same blood group. By applying a strategy of unacceptable mismatches for recipients with an Ab MFI of >5000, only 35 patients (7% of the cohort) were affected, but 22 of these (63%) would have been considered incompatible with >50% of the donors, and 10 would have been considered incompatible with >80% of the donors (Fig. 1) . Using a MFI threshold of >10,000, only 16 patients were affected (3% of the cohort), but half of these would have been considered incompatible with >50% of the proposed donors (Fig.  2) . Considering only those with anti-class II Ab and with a MFI >5000 and >10,000, respectively, 10/14 and 4/8 patients who were considered incompatible with >50% of the donors (Fig. 3) . Among the recipients who received a LT, 22 of the 326 (7%) presented with anti-HLA with an MFI of >5000, and 15 of these would have been considered incompatible with >50% of the donors (including 11 recipients with > 80% of the donors). With the MFI threshold of >10,000, 13 recipients were affected, and 7/13 would have been considered incompatible with >50% of the donors (and 5 would have been considered incompatible with >80% of the donors).
Discussion
aAMR is a relatively uncommon complication after LT. However, it has been reported that aAMR could cause allograft failure in highly anti-HLA sensitized recipients. In a retrospective analysis that included 60 LT recipients with idiopathic early allograft loss (defined as death or retransplantation at <90 days), O'Leary et al. reported a 10% incidence of aAMR in patients with preformed DSAs. (2) Patients who experienced allograft loss caused by aAMR presented with class I and II DSAs and had high MFI scores. AAMR was considered to be the primary cause of allograft failure in 5% of patients, and it was suspected to have contributed to allograft failure in another 5%. (2) In some patients, it has been suggested that the use of B cell targeting agents could improve outcomes. (1, 8, 9) Nevertheless, the increased immunosuppression could also cause neoplastic and infectious complications after treating this type of rejection. (8) cAMR seems to be a more frequent situation, even though, until now, the prevalence of this complication has been little known. The presence of anti-HLA DSAs was previously associated with decreases in patient and graft survival rates. (7, 12, 13) O'Leary et al. investigated the longterm (1 and 5 years) clinical and histological outcomes of patients with or without DSAs. They found that portal and perivenular mononuclear inflammation with low-grade interface necroinflammatory activity, and portal-periportal, sinusoidal and perivenular fibrosis, with or without positive C4d staining, seemed to be associated with cAMR. The authors proposed a score to diagnose "putative chronic antibody-mediated rejection" to predict allograft failure based on interface activity, lobular inflammation, portaltract collagenization, portal venopathy, sinusoidal fibrosis, and hepatitis C virus (HCV) status in cases of positive circulating DSAs and after exclusion of potential confounding causes. However, to date, no management strategy has proven efficacious at improving outcomes in this setting.
In our study, we found that a fifth of our cohort awaiting LT presented with an anti-HLA Ab. As expected, the risk factors for anti-HLA sensitization were blood transfusions, history of pregnancy, and previous transplantation. Most of these patients were considered to be moderate-to-highly sensitized. During the follow-up period, 326 patients received a transplant (67% of the cohort), among which 75 were anti-HLA sensitized and almost half had received a transplant with detectable pDSAs. Using a MFI threshold of >5000, all except 1 of the sensitized patients were affected, and a large majority (61%) was considered to be incompatible (over a 5-year period) with more than half of the proposed liver donors with the same blood group. Using a higher MFI threshold (>10,000), the percentage of liver candidates that were affected was less (3% of the cohort), but 50% were considered incompatible with half of the proposed donors, which is a significant barrier to transplantation.
Considering only class II DSAs, we found similar results, with two-thirds and half of sensitized liver candidates affected by a strategy that included MFI thresholds of >5000 and 10,000. respectively. Similar results have been observed among LT recipients, with 68% presenting with Ab MFI scores of >5000 (22 of 326 recipients), which would have been considered incompatible with >50% of the proposed liver donors. With a MFI threshold of >10,000, 7 of the 13 patients affected would have been incompatible with more than 50% of the proposed donors.
Hence, avoiding pDSAs significantly reduced the donor pool regardless of the MFI threshold used to defined an unacceptable mismatch. Another way to reduce the risk of aAMR and cAMR could be the determination of the most appropriate immunosuppressive regimen in these patients. Actually, no data are available regarding the effect of the use of induction therapy and its type, mainly the use of B cell depleting agents, as well as the impact of avoiding minimization protocols in patients with preformed DSAs. The impact of these strategies on the short-term and longterm outcomes should be assessed.
We were unable to calculate the increased waiting time for anti-HLA sensitized patients for several reasons. First, in France, as in most of countries, organ allocation is based on a severity-related weighting score. Second, anti-HLA are still not tested for systematically in all LT centers: knowledge of their presence is not required by allocation agencies and is not considered during organ allocation. Therefore, based on these 2 reasons, it is actually not possible to evaluate the increased waiting time. However, because livers are generally allocated to the sickest patients, we can speculate that applying a strategy that aims to avoid pDSAs, comparing with the relatively low risk of aAMR or cAMR, may actually increase the risk of death while on a waiting list.
There are some other limitations to our study: we did not assess anti-DP and anti-CW Abs. We also did not test IgG subclasses or whether DSAs were fixing (or not) C1q or C3d. We note that AMR was also frequently reported in patients presenting with C1q-negative DSAs and/or non IgG3 DSAs. (7, 14) In conclusion, avoiding pDSAs affects a small but not negligible proportion of LT candidates. However, in these sensitive patients, avoiding DSAs has the potential to significantly reduce the donor pool, and consequently, transplant accessibility. Thus, the potential risk of pDSAs must be compared with the risk of death occurring while on a transplant waiting list. Consequently, we cannot generalize across this subgroup but, rather, need to assess each patient individually.
